JP2010511626A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511626A5
JP2010511626A5 JP2009539490A JP2009539490A JP2010511626A5 JP 2010511626 A5 JP2010511626 A5 JP 2010511626A5 JP 2009539490 A JP2009539490 A JP 2009539490A JP 2009539490 A JP2009539490 A JP 2009539490A JP 2010511626 A5 JP2010511626 A5 JP 2010511626A5
Authority
JP
Japan
Prior art keywords
alkyl
nhc
compound
independently
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009539490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511626A (ja
JP5211063B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/085962 external-priority patent/WO2008067481A1/en
Publication of JP2010511626A publication Critical patent/JP2010511626A/ja
Publication of JP2010511626A5 publication Critical patent/JP2010511626A5/ja
Application granted granted Critical
Publication of JP5211063B2 publication Critical patent/JP5211063B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009539490A 2006-11-30 2007-11-29 アザ−インドリル化合物及び使用方法 Expired - Fee Related JP5211063B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US60/868,055 2006-11-30
US91762007P 2007-05-11 2007-05-11
US60/917,620 2007-05-11
US94474307P 2007-06-18 2007-06-18
US60/944,743 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2010511626A JP2010511626A (ja) 2010-04-15
JP2010511626A5 true JP2010511626A5 (https=) 2010-12-24
JP5211063B2 JP5211063B2 (ja) 2013-06-12

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539490A Expired - Fee Related JP5211063B2 (ja) 2006-11-30 2007-11-29 アザ−インドリル化合物及び使用方法

Country Status (14)

Country Link
US (1) US7855216B2 (https=)
EP (1) EP2099796B1 (https=)
JP (1) JP5211063B2 (https=)
AR (1) AR064031A1 (https=)
AT (1) ATE511509T1 (https=)
AU (1) AU2007325123B2 (https=)
CA (1) CA2672327A1 (https=)
CL (1) CL2007003444A1 (https=)
DK (1) DK2099796T3 (https=)
PE (1) PE20081354A1 (https=)
PL (1) PL2099796T3 (https=)
PT (1) PT2099796E (https=)
TW (1) TW200829586A (https=)
WO (1) WO2008067481A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526267A (ja) * 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト 化合物および放射性医薬品の製造方法
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CA2806332C (en) * 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of pyrrolopyridine-aniline compounds
IL313821A (en) * 2022-01-28 2024-08-01 Insilico Medicine Ip Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
KR102771568B1 (ko) * 2022-03-04 2025-02-24 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물
US20260048075A1 (en) 2022-08-10 2026-02-19 Vib Vzw Inhibition of TCF4/ITF2 in the Treatment of Cancer
CN121969621A (zh) * 2023-08-02 2026-05-01 英矽智能科技知识产权有限公司 外核苷酸焦磷酸酶-磷酸二酯酶1 (enpp1)抑制剂的结晶形式及其用途
WO2025100940A1 (ko) * 2023-11-07 2025-05-15 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60328675D1 (de) 2002-04-23 2009-09-17 Aventis Pharma Inc 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Similar Documents

Publication Publication Date Title
JP2010511626A5 (https=)
JP2010501584A5 (https=)
JP2024543976A5 (https=)
JP2023535365A5 (https=)
JP2013503846A5 (https=)
JP2009504763A5 (https=)
JP2016518434A5 (https=)
JP2008525416A5 (https=)
JP2011527334A5 (https=)
JP2007518738A5 (https=)
JP2014511892A5 (https=)
JP2012505871A5 (https=)
JP2012530713A5 (https=)
JP2010527913A5 (https=)
JP2009536660A5 (https=)
JP2006151984A5 (https=)
JP2010501478A5 (https=)
JP2011521938A5 (https=)
JP2010540525A5 (https=)
JP2019500387A5 (https=)
JP2010509366A5 (https=)
JP2016506387A5 (https=)
JP2011527335A5 (https=)
JP2011520815A5 (https=)
JP2017523169A5 (https=)